Interventional group#1
Phase 3Small molecule
Interventional group#1 is one of 7 small molecule programs targeting Spinal Anesthesia. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Spinal Anesthesia
#DrugCompanyPhaseTrials
1Decadron
AAspen Global Incorporated
Approved
Catapres
Boehringer IngelheimApproved
Chirocaine
PPurdue Pharma LP
Approved
Anerem
AAcacia Pharma Ltd
Approved
Interventional group#1
KKing Abdulaziz Medical City
Phase 3
Ephedrine Sulfate
DDr. Reddys Laboratories, SA
Preclinical
Dexmedetomidine 5 Micrograms
UUdayana University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Interventional group#1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- KKing Abdulaziz Medical City